News

Published on 12 Sep 2023 on Simply Wall St. via Yahoo Finance

SCYNEXIS, Inc.'s (NASDAQ:SCYX) Stock Is Going Strong: Have Financials A Role To Play?


Article preview image

SCYNEXIS' (NASDAQ:SCYX) stock is up by a considerable 18% over the past three months. As most would know, fundamentals are what usually guide market price movements over the long-term, so we decided to look at the company's key financial indicators today to determine if they have any role to play in the recent price movement. In this article, we decided to focus on SCYNEXIS' ROE.

Return on equity or ROE is a key measure used to assess how efficiently a company's management is utilizing the company's capital. In short, ROE shows the profit each dollar generates with respect to its shareholder investments.

See our latest analysis for SCYNEXIS

NASDAQ.SCYX price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Federated Hermes, Inc. Expands Stake in SCYNEXIS Inc

Overview of Recent Transaction Federated Hermes, Inc., a prominent institutional investor, recent...

GuruFocus.com · via Yahoo Finance 6 Oct 2024

Investors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 87% over the last five years

Long term investing is the way to go, but that doesn't mean you should hold every stock forever. ...

Simply Wall St. via Yahoo Finance 8 May 2024

Shareholders in SCYNEXIS (NASDAQ:SCYX) are in the red if they invested five years ago

We're definitely into long term investing, but some companies are simply bad investments over any...

Simply Wall St. via Yahoo Finance 30 Nov 2023

SCYNEXIS, Inc.'s (NASDAQ:SCYX) Stock Is Going Strong: Have Financials A Role To Play?

SCYNEXIS' (NASDAQ:SCYX) stock is up by a considerable 18% over the past three months. As most wou...

Simply Wall St. via Yahoo Finance 12 Sep 2023

SCYNEXIS (SCYX) Skyrockets 134% Year to Date: Here's Why

SCYNEXIS’ SCYX shares have surged 133.6% year to date against the industry's 1.9% decline. <img a...

Zacks via Yahoo Finance 4 Sep 2023

Avalo Therapeutics, Inc. (AVTX) Reports Q2 Loss, Misses Revenue Estimates

Avalo Therapeutics, Inc. (AVTX) came out with a quarterly loss of $0.59 per share versus the Zack...

Zacks via Yahoo Finance 3 Aug 2023

Scynexis (SCYX) Reports Q1 Loss, Misses Revenue Estimates

Scynexis (SCYX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Esti...

Zacks via Yahoo Finance 11 May 2023

SCYNEXIS, Inc.'s (NASDAQ:SCYX) largest shareholders are individual investors with 51% ownership,...

Key Insights The considerable ownership by individual investors in SCYNEXIS indicates that they c...

Simply Wall St. via Yahoo Finance 8 May 2023

We Might See A Profit From SCYNEXIS, Inc. (NASDAQ:SCYX) Soon

SCYNEXIS, Inc. (NASDAQ:SCYX) is possibly approaching a major achievement in its business, so we w...

Simply Wall St. via Yahoo Finance 12 Apr 2023

Scynexis (SCYX) Inks Antifungal Drug Deal With GSK

Shares of Scynexis SCYX surged almost 76% on Mar 30, after it entered an exclusive license agreem...

Zacks via Yahoo Finance 31 Mar 2023